RE: it may reduce viral load in respiratory secretions but it made no clinical difference according to this study.
The study also states thusly: Further exploration of the factors involved in the oral bioavailability of ivermectin are also warranted.
Therefore, the right POLICY by the FDA or WHO would be to allow doctors anywhere to work with patients under INFORMED CONSENT (e.g, showing them studies like this one ). Not ban the drug and threaten doctors with delicensing if they choose to prescribe it.
This is especially important in places where Monoclonal Antibodies are not available.
I agree only large scale trials will settle the ivermectin question and it may be a while til we have those. In their world countries where monoclonal anti body therapy is not available they have nothing to lose by trying. I hope we are not a third world country yet…despite some politicians efforts to make us one and the focus here as far as Im concerned should be to make monoclonal ab therapy available to all who qualify. If convincing evidence comes out for something else that would change the picture obviously but for. now we go with the best we have. Treatment has evolved considerably i. the last year and I suspect 5 years from now will look quite different from what we are doing today.